EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 170 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,916 | -93.1% | 819 | -91.5% | 0.00% | – |
Q2 2023 | $188,257 | -74.9% | 9,684 | -63.3% | 0.00% | – |
Q1 2023 | $749,422 | -4.5% | 26,416 | -1.6% | 0.00% | – |
Q4 2022 | $785,031 | +12.3% | 26,857 | +1.5% | 0.00% | – |
Q3 2022 | $699,000 | -42.8% | 26,457 | -3.9% | 0.00% | – |
Q2 2022 | $1,223,000 | -10.0% | 27,542 | +0.3% | 0.00% | – |
Q1 2022 | $1,359,000 | -3.7% | 27,461 | -0.9% | 0.00% | – |
Q4 2021 | $1,411,000 | -6.9% | 27,706 | +2.0% | 0.00% | – |
Q3 2021 | $1,515,000 | +40.8% | 27,159 | +8.0% | 0.00% | – |
Q2 2021 | $1,076,000 | -21.5% | 25,139 | -23.4% | 0.00% | -100.0% |
Q1 2021 | $1,371,000 | -16.7% | 32,822 | -7.1% | 0.00% | 0.0% |
Q4 2020 | $1,646,000 | +6.7% | 35,346 | -2.7% | 0.00% | 0.0% |
Q3 2020 | $1,543,000 | +2.7% | 36,315 | +16.0% | 0.00% | 0.0% |
Q2 2020 | $1,502,000 | +13.3% | 31,300 | +8.6% | 0.00% | 0.0% |
Q1 2020 | $1,326,000 | -23.4% | 28,834 | +0.2% | 0.00% | 0.0% |
Q4 2019 | $1,730,000 | +13.1% | 28,790 | +6.5% | 0.00% | 0.0% |
Q3 2019 | $1,530,000 | +3.0% | 27,035 | +1.4% | 0.00% | 0.0% |
Q2 2019 | $1,485,000 | +9.1% | 26,667 | -1.1% | 0.00% | 0.0% |
Q1 2019 | $1,361,000 | +14.4% | 26,951 | -9.4% | 0.00% | 0.0% |
Q4 2018 | $1,190,000 | -41.4% | 29,746 | +1.4% | 0.00% | 0.0% |
Q3 2018 | $2,031,000 | +50.9% | 29,330 | +65.2% | 0.00% | 0.0% |
Q2 2018 | $1,346,000 | +56.7% | 17,758 | +8.5% | 0.00% | 0.0% |
Q1 2018 | $859,000 | -1.0% | 16,373 | +0.9% | 0.00% | 0.0% |
Q4 2017 | $868,000 | -11.2% | 16,231 | -1.0% | 0.00% | 0.0% |
Q3 2017 | $978,000 | -17.3% | 16,403 | +9.5% | 0.00% | 0.0% |
Q2 2017 | $1,182,000 | -1.2% | 14,984 | +3.9% | 0.00% | 0.0% |
Q1 2017 | $1,196,000 | +13.3% | 14,421 | +8.3% | 0.00% | 0.0% |
Q4 2016 | $1,056,000 | +117.3% | 13,317 | +91.6% | 0.00% | – |
Q3 2016 | $486,000 | +737.9% | 6,949 | +355.4% | 0.00% | – |
Q2 2016 | $58,000 | -3.3% | 1,526 | 0.0% | 0.00% | – |
Q1 2016 | $60,000 | -55.6% | 1,526 | 0.0% | 0.00% | – |
Q4 2015 | $135,000 | +20.5% | 1,526 | 0.0% | 0.00% | – |
Q3 2015 | $112,000 | -5.9% | 1,526 | 0.0% | 0.00% | – |
Q2 2015 | $119,000 | – | 1,526 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |